Form 4: Elevance Health CEO Gail Boudreaux Reports Stock Transactions
SEC Form 4
Elevance Health's CEO, Gail Boudreaux, reports the acquisition and disposal of company stock and stock options, including transactions related to tax liability and vesting of restricted stock.
Summary
- Gail Boudreaux, the President and CEO of Elevance Health, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On March 1, 2024, she disposed of 19,256 shares of common stock at $499.11 per share to cover tax liabilities related to vesting restricted stock.
- On the same day, she acquired 8,415 restricted share units and 34,517 performance-based restricted share units, both at a price of $0.
- Following these transactions, Boudreaux directly owns 160,709 shares of Elevance Health common stock and indirectly owns 60 shares through a spouse's revocable trust.
- She also acquired an option to purchase 32,480 shares of common stock at $499.11, exercisable in installments beginning March 1, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing simply reports transactions related to executive compensation, which are expected and routine. There's no indication of positive or negative sentiment towards the company's prospects.
Positives
- The acquisition of 8,415 restricted share units and 34,517 performance-based restricted share units indicates continued alignment with the company's long-term performance.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules for restricted stock units and the exercisability of stock options suggest a continued commitment to the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and directors, which can be informative for investors.
Comparison to Industry Standards
- Executive compensation packages often include a mix of salary, stock options, and restricted stock units to align management's interests with those of shareholders.
- The vesting schedules and exercise prices are typical components of these packages, designed to incentivize long-term performance.
- Comparing the size and structure of Gail Boudreaux's equity awards to those of CEOs at peer companies like UnitedHealth Group (UNH) or CVS Health (CVS) would provide a more comprehensive assessment of her compensation.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation adjustments.
- Shareholders may view the continued equity ownership as a sign of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of stock disposal and acquisition of restricted share units and performance based restricted share units. |
| 03/01/2025 | First vesting date for 2,805 restricted share units. |
| 03/01/2025 | First exercisable date for employee stock option (10,826 shares). |
| 03/01/2026 | Second vesting date for 2,805 restricted share units. |
| 03/01/2027 | Third vesting date for 2,805 restricted share units. |
| 03/01/2034 | Expiration date for employee stock option. |
| 03/05/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.